Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
Optimal early detection and prevention strategies for breast cancer are predicated on our ability to identify individuals at significantly increased risk for this disease. The purpose of this Center is to bring molecular risk prediction for breast cancer into the clinical area. This will require progress on three fronts of scientific endeavor: (i) Establishment of a tissue repository of benign breast disease; (ii) Assessment of potential biomarkers of risk in this tissue set and (iii) Discovery of new, potentially relevant biomarkers of risk. We have made significant progress on these aims. Our current cohort comprises 9,376 women, 758 (8%) of whom have been diagnosed with breast cancer since the time of their benign biopsy. We established our tissue repository of benign breast tissue and have collected the subsequent breast cancer tissue. We assessed the significance of benign histology in predicting risk of future breast cancer, examining in detail the role of proliferative disease, atypia, papillomas, radial scars and involution. We explored the link between centrosome amplification, COX-2 expression and breast cancer outcomes and are currently exploring the significance of p16, ER and MIB-1. We have begun our work with Wayne State to characterize the histopathology in a cohort of African American women. Our focus in 2007-2008 will be on the Wayne State cohort and exploring additional molecular markers.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2007
- Accession Number
- ADA473371
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic